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Tools for noninvasively modulating neural signaling in peripheral organs will advance the
study of nerves and their effect on homeostasis and disease. Herein, we demonstrate a
noninvasive method to modulate speciﬁc signaling pathways within organs using ultrasound
(U/S). U/S is ﬁrst applied to spleen to modulate the cholinergic anti-inﬂammatory pathway
(CAP), and US stimulation is shown to reduce cytokine response to endotoxin to the same
levels as implant-based vagus nerve stimulation (VNS). Next, hepatic U/S stimulation is
shown to modulate pathways that regulate blood glucose and is as effective as VNS in
suppressing the hyperglycemic effect of endotoxin exposure. This response to hepatic U/S is
only found when targeting speciﬁc sub-organ locations known to contain glucose sensory
neurons, and both molecular (i.e. neurotransmitter concentration and cFOS expression) and
neuroimaging results indicate US induced signaling to metabolism-related hypothalamic subnuclei. These data demonstrate that U/S stimulation within organs provides a new method
for site-selective neuromodulation to regulate speciﬁc physiological functions.
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E

very organ contains nerves that regulate the organ’s function. New medical devices are under development that
modulate signals on such nerves to treat disease1,2 (e.g.,
inﬂammatory3, hypertension4, diabetes5, obesity6, and gastrointestinal disorders7,8). However, nerve stimulation strategies
using permanently implanted electrodes3,9,10, transcutaneous
electro-magnetic ﬁelds11,12, or adapted brain stimulation technologies13–16 are limited to stimulating large nerves that can be
accessed by an implanted device (Fig. 1a) or nerves close to the
surface of the skin.
The anatomical structure of the peripheral nervous system
(PNS) presents difﬁcult challenges. Within peripheral nerves,
individual axons are tightly bundled in groups (fascicles) and
wrapped within protective tissue. This makes it difﬁcult to
selectively stimulate subsets of axons that terminate in speciﬁc
organs and uniquely modulate the function of communicating
cells within that organ. Researchers have attempted to develop
increasingly advanced electrode designs9,17 or miniature stimulators18 to implant on smaller nerves near the target. However,
clinical implementation of precision peripheral nerve stimulation
remains elusive. For example, studies of vagus nerve stimulation
(VNS) depend on cervical implants (Fig. 1a) that activate a broad
mixture of efferent1,3,5–7,19–22 and/or afferent5,6,21–23 neural
pathways. And, despite promising VNS trials, low-precision stimulation protocols have not allowed the direct association of
clinical observations with speciﬁc nerve targets without nonspeciﬁc stimulation of other (non-target) neural pathways3,6,21,22.
New nerve-stimulation methods are needed to non-invasively
stimulate speciﬁc targets and correlate organ-speciﬁc neural
activity with function for broad clinical translation.
Previous attempts to utilize U/S to directly stimulate peripheral
nerves alone have focused U/S energy on the same large nerves
(outside the organ) that host implanted electrodes, and this

a

b

Cervical vagal nerve stimulation (VNS):
broad activation of motor and sensory networks

strategy has produced conﬂicting results. Ultrasound focused on
ex vivo nerves has been shown to stimulate nerves (i.e., elicit
action potentials) under a limited set of conditions23–25, or at
powers that may cause damage to the nerve and/or surrounding
tissue24,26. At the same time, in vivo studies have either failed to
elicit nerve activation23, or used indirect methods of measuring
nerve activation via neuromuscular pathways (i.e., measures of
U/S-induced EMG signals or muscle movement)27,28. In contrast,
several reports have demonstrated successful activation of end
axons or nerve terminals in brain tissue29 and retina30. And,
recently the Okusa group has shown activation of the cholinergic
anti-inﬂammatory pathway (CAP)1,3,6,10 using a splenic ultrasound imaging protocol; successfully preventing renal ischemiareperfusion injury in a mouse model of acute kidney injury (AKI)
using an ultrasound imaging scan31. The group linked the
ultrasound effect back to CAP activation through a series of
control experiments, including splenectomy, adoptive transfer
studies of CD4(+) T cells, α7 nicotinic acetylcholine receptor
blockade, and genetic knockout31.
Herein, U/S energy is focused directly on speciﬁc anatomical
targets of neural innervation (Fig. 1b) within the spleen and liver
(without scanning the ultrasound transducer). As discussed
above, neural innervation within the spleen is thought to affect
systemic inﬂammation through the CAP6,19,20. Nerves in the
liver are thought to communicate to the brain and provide a
critical component of the nutrient sensing within the glucoregulation system32. Herein, we demonstrate that both pathways
can be modulated with targeted U/S, and that the non-invasive
U/S technique alleviates endotoxin-induced cytokine production
and hyperglycemia at levels commensurate with traditional,
invasive VNS. Furthermore, unlike cervical VNS (which broadly
stimulates multiple vagal pathways), precision ultrasound neuromodulation enables separate modulation of the splenic

Precision ultrasound (U/S) neuromodulation:
selective neuromodulation of sub-organ physiology
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Fig. 1 Implant-based vagus nerve stimulation (VNS) versus precision ultrasound (U/S) neuromodulation. a A schematic of the neurons within the vagus
nerve, exemplary innervated organs, and the common cervical position used for VNS devices. Stimulation of the cervical vagus results in stimulation of both
target and non-target efferent and afferent pathways1–10. Clinical implementation of miniature stimulators and advanced electrode designs that can be
implanted closer to the target organ (for precision stimulation of axons entering only that organ) is challenging and remains elusive9,17,18. b A schematic of
precision organ-based neuromodulation in which the innervation points of known axonal populations are targeted for stimulation using focused pulsed U/S.
Targets investigated herein include innervation points within the spleen and sensory terminals within the liver
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Fig. 2 Splenic U/S neuromodulation of the cholinergic anti-inﬂammatory pathway (CAP). a The timeline of the U/S neuromodulation performed in the LPSinduced inﬂammation model (see Methods and Supplementary Figures 1–6 for details; stimulation parameters were 1.1 MHz, 136.36 µs pulse length, and
0.5 ms pulse repetition period). b Example U/S image of the spleen used to locate the U/S stimulus (white arrows—outline of the spleen; green arrow—
target point for U/S stimulation). c–e Splenic concentrations of CAP signaling molecules, including norepinephrine (c), acetylcholine (d), and TNF (e) are
shown for naive animals, sham controls (LPS, -U/S), and with U/S stimulation (0.03–1.72 MPa). f Whole-blood concentrations of TNF for the same
conditions as (e). The asterisks mark statistical signiﬁcance using two-sided t-test versus LPS only controls (with p-value thresholds; *p < 0.05, **p < 0.01,
***p < 0.001). n = 5 for all experiments in this ﬁgure except for all LPS − (U/S) controls which were n = 7

(anti-inﬂammatory) versus the hepatic (metabolic) pathways.
The splenic stimulation data demonstrates a clear ultrasound
“dose response” to norepinephrine with a distinct power level
required for cytokine reduction in the endotoxin model, and an
effective power range commensurate with potential clinical use.
Both the splenic and hepatic stimulation data are presented with
direct measurements of U/S-induced neuromodulation (i.e.,
neurotransmitter concentration in the spleen experiments, and
cFOS and DfMRI data in the liver experiments), and indirect
measurements of effects on down-stream signaling pathways
(i.e., kinase activities for several important/relevant intracellular
signaling pathways). Finally, chemical/mechanical blocking and
genetic knock-out experiments are shown for several signaling
components in the splenic pathway, and data on the effect of
these knock-outs on ultrasound-induced activation of CAP is
reported. These results, combined with our companion paper by
Zachs et al. (that demonstrates the use of splenic U/S stimulation
to reduce disease severity in a preclinical model of inﬂammatory
arthritis), provide the most thorough report to date on the
potential for precision ultrasound stimulation to replace
implantable devices for the translation of peripheral
neuromodulation-based therapies1,2.
Results
Targeted sub-organ ultrasound neuromodulation. In splenic
stimulation experiments, the output of each cell type involved in
the CAP (using the LPS-induced acute inﬂammation rodent
model under different U/S stimulation conditions) was monitored (Fig. 2a, b; see Methods for details of U/S stimulation and
the LPS model6,19–22). The CAP (Fig. 1b) includes three major

cell types: the end axon terminals that project from the splenic
ganglia, intermediary T-cells, and macrophages that release
cytokines systemically. Electrical stimulation of this pathway is
well studied; neuromodulation affects cytokine production and
potentially provides therapeutic beneﬁt in several chronic
inﬂammatory diseases3,7. Figure 2b shows an example U/S image
used to non-invasively target the U/S stimulus (see Methods and
Supplementary Figures 1–5 for details on image guidance).
Unlike previous examples of ultrasound stimulation31, the
ultrasound stimulus was not swept across the organ or focused on
a large nerve outside the organ, but rather targeted to speciﬁc
locations of nerve innervation within the organ (see Supplementary Figure 5 for details of estimated stimulation areas within
the organs). We evaluated CAP response to the targeted US stimulation by measuring splenic concentrations of CAP-related
neurotransmitters and cytokines including norepinephrine (NE),
acetylcholine (ACh), and tumor necrosis factor (TNF; see
Methods for ELISA and HPLC procedures; see Supplementary
Figure 6 for data in LPS-naive animals). A 1.1 MHz U/S transducer was focused directly on splenic targets using U/S coupling
gel. Figure 2c–f shows the measured CAP response in control
rodents (those having received LPS and not U/S stimulation), and
in U/S-treated rodents. Splenic NE levels averaged 140 nmol/L in
naive animals, whereas the LPS controls dropped NE levels to
near zero, demonstrating suppression of CAP signaling during
LPS-induced inﬂammation. The U/S stimulus attenuated the LPS
response toward levels measured in naive animals (Fig. 2c).
Consistent with the CAP signaling process, the NE increase in the
U/S-stimulated animals correlated with a splenic ACh increase
and, at 0.83 MPa U/S pressure, the average ACh concentration
was nearly three times that found in the sham animals (Fig. 2d).
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Fig. 3 Lasting effect of splenic U/S neuromodulation. a Splenic IL-1α concentrations measured from the same samples as Fig. 2c–e. n = 5 for all
experimental conditions, except LPS–(U/S) controls which were n = 7. b Study timeline and data designed to measure the concentrations of splenic TNF
after response times of 1–3 h (i.e., the time the sample was harvested post treatment). n = 4 for each experimental condition. c Normalized concentrations
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Also, both splenic (Fig. 2e) and circulating (Fig. 2f) TNF levels
were signiﬁcantly reduced compared to the sham animals.
Treatment response depended on U/S pressure, and the doseresponse curve showed the most effective pressure parameters to
range between 0.25 and 0.83 MPa (parameters corroborated in
our companion paper by Zachs et al.).
The broader impact of U/S stimulation on CAP-related intraand extracellular signaling pathways, and the kinetics of the U/S
effect were also investigated. In addition to TNF, U/S stimulation
also signiﬁcantly reduced splenic interleukin-1-alpha (IL-1α)
levels (Fig. 3a). The maximum U/S-mediated response to LPSexposure occurred 1–2 h after treatment (Fig. 3b), showing
kinetics similar to previous implant-based-VNS studies6,19–21. To
further characterize the effect, we measured U/S activation of
speciﬁc intracellular kinases (Fig. 3c) that are associated with
LPS-33, CAP-34, or TNF-α-mediated35 signaling. These data show
that U/S strongly enhanced activation of some kinases (e.g., p38
and p70S6K), and the U/S pressure-dependent response of some
kinases (e.g., p38) approximately correlated with the U/S pressure
dependence of neurotransmitter and cytokine concentrations
previously observed (Fig. 2c–e). Finally, splenic U/S showed a
persistent suppressive effect when applied before the LPS
injection (Fig. 3d), also consistent with previous invasive VNS
studies6,19–21. Figure 3d shows that this protective effect
continued well after treatment, and a single U/S treatment
produced a statistically reduced TNF response to endotoxin up to
48 h after U/S stimulation. In corroboration, our companion
paper by Zachs et al. (using a serum-transfer arthritic mouse
model), independently showed that non-invasive splenic U/S
stimulation alleviated the severity of arthritis, and that this
4

ultrasound-speciﬁc effect (using the same optimal ultrasound
frequency, and similar stimulation pressure) was apparent when
administered before or after induction and manifestation of the
disease.
To further conﬁrm the role of the CAP in mediating the
suppressive effects of splenic U/S stimulation, we performed tests
in additional knock-out and denervation models (Fig. 4),
including nude mice (lack functional T cells; Fig. 4a), CD4 ChAT
(choline acetyltransferase) knock-out mice (genetic ablation of
ChAt in CD4+ T cells Fig. 4a), α7nACh receptor (Fig. 4a) knockout mice, and reserpine-treated mice (inhibited catecholamine
production; Fig. 4b). The Methods section contains descriptions
of the methods used to create each knock-out model, and the
protocol for reserpine-based depletion of catecholamine stores.
Splenic U/S stimulation induced signiﬁcant suppression of
endotoxin-induced systemic TNF levels in wild type C57black/6
mice (Fig. 4a), similar to that observed in the endotoxemic rats
(Fig. 2). To study the role of T cells, we carried out splenic U/S
stimulation in nude mice. Splenic U/S stimulation failed to induce
suppression of LPS-induced TNF in nude mice indicating that
functional T cells are required for U/S-mediated suppression
(Fig. 4a). Next, to identify whether acetylcholine-producing
T cells are required for U/S-mediated suppression, we used CreloxP recombination in mice to selectively ablate ChAt in CD4+
T cells. Splenic U/S stimulation in CD4 ChAT KO mice did not
alter TNF levels signiﬁcantly, as compared with controls
indicating that U/S stimulation requires acetylcholine producing
T cells for mediating TNF suppression (Fig. 4a). Macrophages are
a major source of TNF production during endotoxemia, and
α7nAChR expressed on macrophages plays a critical role in
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endotoxemia through CAP. a Splenic concentrations of TNF are shown for
sham controls (LPS, -U/S) and U/S stimulated mice (0.83 MPa ultrasound
setting) for C57black/6 mice, Nude mice, CD4 ChAT knock-out mice, and
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Methods for details) mice. All experiments in this ﬁgure were performed
using the same U/S settings as in Figs. 2 and 3 (0.83 MPa)

mediating cholinergic anti-inﬂammatory signaling36. Accordingly, we tested the effect of splenic U/S stimulation in animals
lacking α7nAChR expression. As shown in Fig. 4a, U/S
stimulation did not suppress TNF levels during endotoxemia in
α7nAChR KO mice. Splenic U/S stimulation leads to a signiﬁcant
increase in splenic norepinephrine levels in endotoxemia model
(Fig. 2b). To further assess the role of catecholamines in this
pathway, we performed splenic U/S stimulation in endotoxemic
mice previously depleted of catecholamine stores by treatment
with reserpine. Splenic U/S stimulation attenuated systemic TNF
levels in control animals but not in reserpine-treated animals
(Fig. 4b). Together, these ﬁndings indicate that splenic U/S
stimulation attenuates TNF production during endotoxemia
through CAP and provide further evidence of a neuromodulatory
mechanism versus a direct ultrasound effect on splenic immune
cells.
The effect of splenic U/S neuromodulation was then compared
to standard implant-based VNS (see Methods for VNS details).
Figure 5a shows that invasive cervical VNS and noninvasive
splenic U/S stimulation have a nearly equivalent effect on TNF
(see the U/S stimulation (left) and VNS implant stimulation
(right) bars without the addition of kinase inhibitors (- PP2, -LY,
and -PD)). Furthermore, Fig. 5b shows that splenic injection of αbungarotoxin (BTX, a known antagonist for the α7nACh receptor
central to CAP signaling19–22) suppressed the effect of U/S
stimulation on TNF-α concentration (demonstrating that, like
VNS-based CAP activation3,19–22, optimal CAP modulation by
U/S requires splenic α7nAChR signaling). Consistent with the
CAP model (Fig. 1b), NE concentration was unaffected by BTX
(i.e., BTX blocked the effect of elevated NE through the α7nAChR
pathway, and not through modiﬁcation of neurotransmitter
release itself). Vagotomy also suppressed CAP modulation by U/S
(Fig. 5b), providing suppression of the effect of U/S stimulation
on TNF concentration to the same level as BTX. However,
vagotomy failed to inhibit the effect of U/S on NE concentrations
within the spleen during the LPS experiments, suggesting that
cervical vagotomy may not immediately affect the ability of local
splenic tissue (down-stream of the vagotomy) to respond to the

ARTICLE

ultrasound stimulus. This data showing attenuation of the U/Sinduced TNF suppression without a change in post-U/S NE
concentrations may also be explained by more recent studies of
the vagal anti-inﬂammatory pathway suggesting other locations
of the critical α7nACh receptor22. Finally, the kinase inhibitors
PP2
(4-amino-5-(4-chlorophenyl)-7-(dimethylethyl)pyrazolo
[3,4-d]pyrimidine, partially selective for Src kinase) and
LY294002 (PI3-kinase selective) were shown to suppress the
U/S effect, while PD98059 (MEK1- and MEK2-selective MAPK
inhibitor) showed no effect (Fig. 4a). These results corroborate
those in Fig. 3c, in which U/S stimulation altered kinase
activation within the CAP34 and TNF35 related PI3 (i.e., Akt,
P70S6K), c-Src, and p38-MAPK pathways, but not kinases
involved in direct bacterial antigen response (i.e., GSK3B).
The physiological speciﬁcity of focused U/S stimulation was
then investigated by measuring several known side effects of
invasive VNS. Figure 5c shows the change in heart rate caused by
cervical VNS or splenic U/S neuromodulation (see Methods for
heart rate measurement details). At 2- and 5-V VNS intensities,
heart rate signiﬁcantly decreased. However, local splenic U/S
neuromodulation showed no effect on heart rate. Stimulation of
off-target sites (i.e., liver) did not modulate the LPS-induced TNF
response; however, U/S stimulation at several different sites
within the spleen provided similar modulation of the TNF
response (Fig. 5d). Interestingly, Fig. 5e shows that splenic U/S
stimulation had no effect on blood glucose concentration,
whereas VNS experiments exhibited the previously-observed side
effect of attenuating LPS-induced hyperglycemia. It is hypothesized that this metabolic side effect of CAP-targeted VNS6 may be
due to off-target VNS of a second (non-CAP) vagal pathway.
Precise stimulation of sensory sites in the liver. VNS has been
shown to reduce hyperglycemia5,6. To investigate whether this
was associated with neuromodulation of hepatic sites, VNS was
compared with our precision U/S stimulation technique applied
to the liver. Figure 6a shows the U/S-image guidance that enabled
locating the U/S stimulus at the porta hepatis region of the liver,
which contains glucose-sensitive neurons known to signal to and
modulate metabolic control centers within the hypothalamus37.
We found that hepatic U/S stimulation provided protection
against LPS-induced hyperglycemia, as Fig. 6b shows that U/S
stimulation limited the increase in blood glucose levels to within
post-prandial concentrations. Furthermore, this effect was anatomically speciﬁc. Figure 6b shows that locating the stimulus
toward the right or left lobe of the liver reduced the effect of U/S
stimulation. Furthermore, hepatic concentrations of local signaling molecules associated with glucose metabolism showed that
U/S stimulation did not show direct changes within the liver
indicative of direct modulation of hepatic glycolytic or glycogenolytic processes (Fig. 6c, gray bars). Instead, it was found that
U/S stimulation of the sensory neuron containing porta hepatis
region resulted in signiﬁcantly reduced hypothalamic concentrations of NPY and increased hypothalamic insulin receptor
substrate (IRS-1) and protein kinase B (pAkt) activation (Fig. 6c,
blue bars). The increase in IRS and pAkt phosphorylation indicates increased insulin signaling in the hypothalamus, which is
capable of driving the observed reduction in concentrations of
NPY. These results are consistent with previous reports of LPSinduced dysregulation of insulin-mediated IRS1-P13 signaling38.
Interestingly, these results also suggest that altered signaling
through the central nervous system may be involved in the role
that chronic inﬂammation (i.e., metabolic endotoxemia) has been
shown to play in the pathogenesis of insulin resistance39,40.
Having observed this response in the brain, we sought to verify
that neurons within afferent pathways were being modulated
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(left; stimulation at 0.83 MPa) versus implant-based VNS (see Methods for details) treated animals (concentrations are shown as a percent change
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(MEK1- and MEK2-selective MAPK inhibitor). n = 4 for each experimental condition. b Data showing the effect of α-bungarotoxin (BTX) or surgical
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shown compared to pre-injection concentration at times of 5, 15, 30, and 60 min for the unstimulated controls (blue-circles), splenic U/S stimulation
(purple-triangles), or cervical VNS (light blue-squares). n = 12 for each experimental condition. All experiments in this ﬁgure were performed using the
same U/S parameters as Figs. 3 and 4

upon hepatic U/S stimulation (Supplementary Figure 11 contains
a description of known afferent and efferent neural pathways
involved with glucose regulation and homeostasis that interact
with the hypothalamus). The U/S-induced neuromodulation was
ﬁrst quantiﬁed by measuring the expression of the immediate
early gene c-Fos within deﬁned hypothalamic and brainstem subnuclei known to modulate glucose homeostasis (Fig. 7a, c and
Supplementary Figure 12, respectively)37,41. Compared to the
controls, there was signiﬁcant changes in the number of c-Fos
positive (c-Fos+; Fig. 6a) cells within the paraventricular nucleus
(PVN), dorsomedial nucleus (DMN), ventromedial nucleus
(VMN), arcuate nucleus (ARC), and lateral hypothalamus (LH),
suggesting U/S-induced modulation of the LPS-induced glucoregulatory neural signaling. These data corroborate the previous
ﬁnding that ultrasound stimulation is modulating hypothalamic
insulin sensitivity (Fig. 6c), which results in changes in nerve
activity that are known to alter signals to the PVN (and outgoing
or peripheral metabolic regulation)37–39,42,43. Furthermore, the
altered hypothalamic c-Fos expression was accompanied by
increased c-Fos expression within the nucleus tractus solitaris
(NTS; Supplementary Figure 12), suggesting U/S-mediated
modulation via signaling through afferent pathways (see Methods
for immunohistochemistry details).
6

To further support the previous ﬁnding, the apparent diffusion
coefﬁcient (ADC) from diffusion-weighted functional magnetic
resonance imaging (DfMRI) images in the hypothalamic subnuclei were compared before and after hepatic U/S stimulation.
DfMRI44–46 is a technique that is still under development that has
recently been shown sensitive to changes in nerve activity driven
by external neuromodulators47 (see Methods, Supplementary
Figures 13 and 14, and Supplementary Table 2 for DfMRI
details). In response to the U/S stimulus, the ADC changed
signiﬁcantly within the PVN, corroborating both the chemical
(POMC, NPY) and c-Fos expression data, which demonstrated
U/S-induced modulation of LPS-activated pathways communicating to the hypothalamus. Figure 7b shows an exemplary
t-test map (top image) showing this U/S-mediated change in
ADC (suggesting changes in ultrasound modulated neural
activity44–47). Figure 7d summarizes the ADC change within
the PVN across all experiments (including data from the animal
shown in Fig. 7b). DfMRI (though newly developed47) is useful
herein in examining changes in nerve activity driven by the
external ultrasound neuromodulation. And, when viewed
together the DfMRI, cFos, and hypothalamic neurochemistry
results, provide a set of data that are mutually consistent
with ultrasound activation of a pathway that modulates the
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glucose concentrations compared to pre-injection concentration are shown at times of 5, 15, 30, and 60 min. The data show reversal of LPS-induced
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same U/S parameters as Figs. 3–5

LPS-induced effect on energy metabolism via the NPY system
and its effect on outgoing PVN signaling42,43.
Discussion
In this work, we demonstrated noninvasive neuromodulation
through sub-organ U/S stimulation of targeted sites of nerve
innervation. Our technique uses focused US to target the innervation points and areas of speciﬁc synaptic connection and
physiological function. This approach employs the natural hierarchical structure and organization of the nervous system,
enabling precision neuromodulation with a noninvasive stimulation technology. Ultrasound modulation of two completely
different organs and distinct physiological pathways (the CAP in
the spleen and metabolic sensory neurons/cells in the liver) was
achieved with the same technology. This opens the potential for
applying this method to modulate other peripheral signaling
pathways, providing a new U/S tool to map the
structure–function relationship between the PNS and physiological organ function in health and disease.
With respect to the splenic CAP pathway, a recent study has
shown that enhancement of CAP signaling through implantbased VNS inhibits production and circulation of cytokines (i.e.,
TNF, IL-1β, and IL-6) in humans3, as it did in the previous preclinical models1,2,6,7,10,21,22. In addition, VNS signiﬁcantly
inhibited TNF production in a whole blood assay for up to
84 days, and positively affected disease severity in a pilot study
with rheumatoid arthritis patients3. As the ﬁrst of its kind study,
it shows the potential to use neuromodulation therapies in diseases that are currently treated with drugs. However, larger studies will be necessary to further analyze risk versus beneﬁt for
using implantable nerve stimulators to replace pharmacological
treatments.
As an interesting alternative, researchers in our companion
paper by Zachs et al. showed that splenic ultrasound stimulation
was effective in reducing disease severity in a mouse model of
inﬂammatory arthritis (using chosen U/S stimulation parameters
and intensities that are substantiated by our data). A separate
research group31, has also recently published the use of an imaging or transducer scanning method of applying ultrasound to the
spleen to activate CAP and modify disease (i.e., prevention of

renal ischemia-reperfusion injury in a mouse model of AKI).
Herein, we demonstrated that precision ultrasound application
(without scanning the transducer or ultrasound energy) is also
adequate to activate CAP. In addition, results from the reserpine/
catecholamine depletion experiments demonstrated that this
effect is dependent on ultrasound interaction with the nervous
system (or interfacing cells), providing further evidence of use of
the technique as a non-invasive method of neuromodulation.
This ﬁrst report of precision or local nerve activation (using a
tightly focused and image targeted ultrasound beam) demonstrates the potential to use ultrasound as a less invasive alternative
to implant-based neuromodulation and opens novel paths toward
clinical translation of bioelectronic medicines1,2.
To demonstrate this potential, our team applied the precision/
image-targeted ultrasound stimulus to a non-CAP nerve target
for the ﬁrst time (the hepatic target, previously hypothesized to
harbor glucose sensory neurons37,41). Our results corroborate
previous studies that utilized glucose clamp methods to control
concentrations and/or ﬂuctuations in circulating glucose levels,
and thus signaling from those glucose/nutrient sensing neurons
in peripheral organs37,43. These early clamping techniques (which
require isolation of local blood circulation, such as portal blood,
from systemic blood) are difﬁcult, and therefore limit the number
of studies that attempt to identify the speciﬁc roles of peripheral
sensory neurons in metabolic homeostasis. In contrast, the
technique described herein represents a new method for modulating peripheral sensory output experimentally and may enable
a new wave of research on the contribution of peripheral sensing
and signaling in health and disease.
Continued work will be needed to further explore the potential
of precision ultrasound neuromodulation. Supplementary Figure 5
provides schematics showing the level of precision obtained
herein in stimulating speciﬁc anatomical targets. Both liver and
hepatic stimulation experiments were performed with portions of
the stimulation ultrasound beam extending slightly beyond the
target organ (approximately, 2 mm beyond the organ for splenic
stimulation and <0.5 mm for hepatic stimulation). Application of
new ultrasound transducer technology may be utilized in future
experiments to increase the level of stimulus precision48–50. Still,
the data herein represents the ﬁrst report in which a targeted
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Fig. 7 Histochemical and DfMRI analysis of neural pathways associated with response to hepatic U/S stimulation. a cFOS immunohistochemistry images
showing the number of activated neurons in the (top) unstimulated control and (bottom) U/S-stimulated animals. Images were segmented on the
paraventricular nucleus (yellow; PVN), dorsal medial nucleus (green; DMN), ventromedial nucleus (red; VMN), arcuate nucleus (dark blue; ARC), and
lateral hypothalamus (purple; LH). Scale bar = 300 microns. b Example MRI overlays between activation maps and the T1 SPGR volume (top; see Methods
for details) and a brain atlas overlay on the T1 SPGR volume (bottom; see Methods, Supplementary Figures 13 and 14, and Supplementary Table 2 for
further details). The blue color in the top image denotes regions where ADC changed signiﬁcantly post-U/S. Each color in the bottom image represent
anatomically distinct brain regions in the atlas; major areas showing decreased ADC (top image; red arrows) aligned with the left (brown) and right (light
green) PVN in the bottom image (red arrows). c Data showing the percent change of the number of cFos expressing cells in the US stimulated animals
(n = 8) compared to sham controls (n = 6) in each of the segmented hypothalamic regions (PVN, DMN, VMN, ARC, and LH), images in (a) represent one
set of sham versus stimulated paired animals. d T-test values from corresponding-pixel comparison within PVN ROIs (see Methods for details) between
the pre- and post-treatment ADC maps showing increased ADC values (compared to controls) for the 6 animals tested after U/S stimulation, images from
(b) represent results from one exemplar animal. All experiments in this ﬁgure were performed using the same U/S parameters as Figs. 3–6, except the
DfMRI experiment in which a MR compatible ultrasound transducer was needed. The compatible ultrasound transducer had an acoustic frequency of
1.47 MHz. The band inside the box shows the second quartile, while the whiskers represent the minimum and maximum of all the data

ultrasound tool enabled stimulation of multiple points within a
single organ (i.e., stimulation of the porta hepatis region versus
right or left lobe, Fig. 6), and this initial experiment has already
yielded an observation of differential effects based on stimulus
location. The data herein also represents the ﬁrst time that a
neuromodulation technique has been used to separately attenuate
LPS-induced cytokine versus hyperglycemic effects, showing
speciﬁcity beyond that available with cervical VNS (Fig. 5). These
initial results suggest that further investment and research into
the use of ultrasound for peripheral neuromodulation is justiﬁed
and will require increased collaboration between ultrasound
device engineers and neuroscientists.
The results herein also add data to the continued debate
around the exact mechanism of ultrasound in neuromodulation
experiments23–30,51. Supplementary Table 1 provides additional
detail comparing the ultrasound parameters used herein to
standard clinical measures (MI (mechanical index) and TI
(thermal index)) used to assess the potential for heating (TI) or
cavitation-based (MI) bioeffects of ultrasound52. The ultrasound
parameters utilized in the above experiment remain below those
expected to heat tissue to temperatures currently known to
8

activate heat-sensitive ion channels16,53 or produce cavitation, in
agreement with previous reports that have suggested a direct
mechanical activation of brain or neural tissue (or surrounding/
supporting cell and tissue structures)29. The reserpine/catecholamine depletion experiments shown herein also suggest a nervemediated mechanism of ultrasound neuromodulation in peripheral organs; however, the results shown above do not speciﬁcally
identify the cellular or molecular components associated with
transduction of the ultrasound energy. Further studies of ultrasound stimulation in in vitro models of organs or organoids
(under direct microscopic observation) will be necessary to elucidate the speciﬁc molecular transduction pathway of the ultrasound stimulus.
Future translation to the clinic will also come with challenges.
As shown in this manuscript, ultrasound parameters shown to
provide neuromodulatory effects fall within the range of those
currently utilized in the clinic (Supplementary Table 1). However,
human organs are larger than the pre-clinical organ targets studied herein, and similar clinical “dosing” studies (as shown
herein in pre-clinical model data above, and Supplementary
Figures 8–10) will be needed to determine the effect of precision
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ultrasound stimulation in human anatomy. In addition, there will
exist heterogeneity in human patient populations, including body
mass index, bone and skeleton size and shape, and nerve/organ
location. The tools utilized to test ultrasound-based neuromodulation in the clinic will require the sophistication to adjust
stimulation targeting and parameters, such that each patient will
receive a known and controlled ultrasound “dose”. Our team is
currently designing and building the tools required to achieve
precision neuromodulation in both additional pre-clinical models
of disease (including models of sepsis, obesity, and diabetes) and
within clinical environments. These on-going studies will further
test for broad application of non-invasive U/S stimulation to a
variety of anatomical and organ targets and determine if these
tools translate to the application in a wide range of health
disorders.
Methods
Focused ultrasound (FUS) probe set-up and characterization. A block diagram
of the focused ultrasound (FUS) system is shown in Supplementary Figure 1. The
system consists of a 1.1 MHz, High Intensity Focused Ultrasound (HIFU) transducer (Sonic Concepts H106), a matching network (Sonic Concepts), an RF power
ampliﬁer (ENI 350L) and a function generator (Agilent 33120A). The 70-mmdiameter HIFU transducer has a spherical face with a 65-mm radius of curvature. It
has a 20-mm-diameter hole in the center into which an imaging transducer can be
inserted. The transducer depth of focus is 65 mm. The numerically simulated
pressure proﬁle has a full width at half amplitude of 1.8 mm laterally and 12 mm in
the depth direction. The HIFU transducer is acoustically coupled to the animal
through a 6-cm-tall plastic cone ﬁlled with degassed water.
The function generator produces a pulsed sinusoidal waveform, shown
schematically in Supplementary Figure 2. This pulsed sinusoidal waveform is
ampliﬁed by the RF power ampliﬁer and sent to the impedance-matching network
connected to the HIFU transducer. For most of the animal experiments, the pulse
center frequency was 1.1 MHz, the pulse repetition period was 0.5 ms
(corresponding to a pulse repetition frequency of 2000 Hz); the pulse amplitude
and pulse length varied. Supplementary Table 1 lists the combinations of pulse
amplitude and length that were used in the experiments; the third column lists the
peak ultrasound pressure at the focus derived from the pulse voltage amplitude.
The voltage-to-pressure calibration of the HIFU transducer was performed in
degassed water using a needle hydrophone (ONDA HNA-0400). The HIFU
transducer was driven by a 100-cycle sinusoidal voltage waveform. To locate the
position of peak pressure, the hydrophone was scanned in a neighborhood of the
nominal transducer focus point in 0.1 mm steps in the lateral plane and in 0.2 steps
in the depth direction. Supplementary Figure 3 shows a scan through a plane at the
depth of focus. For driving voltages below 60 V, the nonlinearity of water was
small, i.e., the maximum negative pressure and the maximum positive pressure
were nearly equal, and the pressure varied linearly with driving voltage.
Ultrasound targeting for organ-speciﬁc neuromodulation. A Vivid E9 ultrasound system (GE Healthcare) or an 11L probe (GE Healthcare) were used for the
ultrasound scan before neuromodulation started. Supplementary Figure 4 shows
the images of the rat spleen (Supplementary Figure 4A) and rat liver (Supplementary Figure 4B). The HIFU transducer was positioned on the target area based
on this initial image. Another ultrasound scan was also performed using a smaller
imaging probe (3S, GE Healthcare), which was placed in the opening of the HIFU
transducer (Supplementary Figure 4C). The imaging beam of the 3S probe was
aligned with the U/S beam. Therefore, one could conﬁrm that the U/S beam was
targeted at the region of interest using an image of the targeted organ (visualized on
the Vivid E9). After the organ of interest was identiﬁed, the transducer position was
marked on the animal’s skin and the HIFU transducer was positioned on the
marked area, ultrasound stand-offs were utilized to adjust depth for the appropriate
organ target.
Animal models and ultrasound stimulation protocol. Adult male
Sprague–Dawley rats 8–12 weeks old (250–300 g; Charles River Laboratories) were
housed at 25 °C on a 12-h light/dark cycle and acclimatized for 1 week, with
handling, before experiments were conducted to minimize potential confounding
measures due to stress response. Water and regular rodent chow were available ad
libitum. Experiments were performed under protocols approved by the Institutional Animal Care and Use Committee of GE Global Research.
Endotoxin (lipopolysaccharide (LPS) from Escherichia coli, 0111: B4;
Sigma–Aldrich) was used to produce a signiﬁcant state of inﬂammation and
metabolic dysfunction (e.g., hyperglycemia and insulin resistance) in naive adult
Sprague–Dawley rats. LPS was administered to animals (10 mg/kg), which
corresponds to an approximate LD75 dose, via intraperitoneal (IP) injection
causing signiﬁcant elevation in concentrations of TNF, circulating glucose, and
insulin; these concentrations peak in 4 h but remain elevated as compared to
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control for up to 8 h post injection. After LPS administration, spleen, liver,
hypothalamic, hippocampal, and blood samples were harvested at 60 min for most
studies; at 1, 2, and 3 h for kinetic studies (Fig. 2e) and at 0.5, 1, 2, 4, 8, 24, and 48 h
for duration studies (Fig. 2g, h). Spleen and liver samples were prepared as
described below. Samples were analyzed by enzyme-linked immunosorbent assay
(ELISA) for changes in cytokine (Bio-Plex Pro; Bio-Rad), tumor necrosis factor
alpha (TNF) (Lifespan) and acetylcholine (Lifespan) concentration as described
below. Catecholamine concentrations were assessed using high performance liquid
chromatography (HPLC) detection and ELISA (Rocky Mountain Diagnostic)
analysis as described below.
The link between LPS and insulin resistance is well detailed in the literature
with hyperglycemia and hyperinsulinemia frequently observed during bacterial
infection as an indicator of poor clinical outcome in patients. Thus, to follow the
effects of LPS and US treatment on blood glucose and insulin levels, blood samples
were obtained from the tail vein at 0, 15, 30, and 60 min after LPS injection. Blood
glucose concentrations were measured by a OneTouch Elite glucometer (LifeScan;
Johnson & Johnson). Insulin concentrations in plasma, obtained from blood, were
determined using an ELISA kit (Crystal Chem). Signal transduction changes were
measured by assessment of key biomarkers including: p38, p7056k, Akt, GSK3B,
c-Src, NF-κβ, SOCS3, IRS-1, NPY, and POMC in liver, muscle, cardiac, and
hypothalamic tissue samples.

Mice. All mice experiments were performed under protocols approved by the
Institutional Animal Care and Use Committee of the Feinstein Institute for
Medical Research, Northwell Health System. Animals were housed at 25 °C on a
12-h light/dark cycle, and acclimatized for at least 1 week before conducting
experiments. Water and regular rodent chow were available ad libitum. Wild type
C57black/6 mice, nude (nu/nu) mice, α7 nicotinic receptor knock out mice
(B6.129S7-Chrna7tm1Bay, number 003232), ChAT-ﬂoxed (B6.129-Chattm1Jrs/J),
and mice expressing Cre recombinase under the control of the endogenous CD4
promoter (CD4-Cre), 8–12 weeks old (20–25 g) were purchased from The Jackson
Laboratory (Bar Harbor, ME, USA). ChAT-ﬂoxed and CD4-Cre mice were crossed
to generate mice genetically devoid of ChAT in the CD4+ population.

Catecholamine depletion. Reserpine (Sigma–Aldrich) dissolved in glacial acetic
acid (Sigma–Aldrich) was diluted with sterile saline to a ﬁnal glacial acetic acid
concentration of 0.5%. Mice received intraperitoneal administration of reserpine
(10 mg/kg) reserpine 24 h before the beginning of experiments.

Ultrasound stimulation protocol. The protocol used for ultrasound neuromodulation was as follows. Animals were anesthetized with 2–4% isoﬂurane. The
animal was laid on a water circulating warming pad to prevent hyperthermia
during the procedure. The region above the designated point for U/S stimulus
(nerve of interest) was shaved with a disposable razor and animal clippers prior to
stimulation. A Vivid E9 Diagnostic imaging ultrasound system was used to identify
the region of interest as follows. Liver: the porta hepatis as indicated by Doppler
identiﬁcation of the hepatic portal vein. Spleen: visual identiﬁcation of the spleen
by diagnostic ultrasound. Location of stimuli was maintained along the splenic axis
as identiﬁed. The area was marked with a permanent marker for later identiﬁcation. Ultrasound stimulation was applied using a research FUS system. The U/S
probe was placed at the designated area of interest identiﬁed by the diagnostic
ultrasound probe (Supplementary Figures 1 and 4). An U/S stimulus was then
applied with total duration of a single stimulus not surpassing a single 1 min pulse.
At no point was the energy allowed to reach levels associated with thermal damage
and ablation/cavitation (35 W/cm2 for ablation/cavitation). LPS (10 mg/kg) was
then injected IP (for acute/kinetic studies). Alternatively, for duration of effect, LPS
was not injected here and was instead injected at a later designated time point.
Second 1-min US stimuli may then be applied.
The animal was then allowed to incubate under anesthesia, due to the
concentration of LPS being equivalent to an LD75 dose, for acute (1-h) and kinetic
(varying up to a maximum of 3 h post LPS) studies. After incubation, the animal
was euthanized and tissue, blood samples are collected as described below. For
duration of effect studies, LPS was not injected at the time of U/S stimulus but
rather at a designated delay after the U/S stimuli have been applied (e.g., 0.5, 1, 2, 4,
8, 24, or 48 h). After the delay, the animal was placed into an anesthetic holding
chamber and monitored until euthanasia and tissue/ﬂuid collection.

Tissue harvesting and sample preparation. An incision was made starting at the
base of the peritoneal cavity extending up and through to the pleural cavity. Organs
(including spleen and liver) were rapidly removed and homogenized in a solution
of phosphate-buffered saline (PBS), containing phosphatase (0.2-mM phenylmethylsulfonyl ﬂuoride, 5-µg/mL aprotinin, 1-mM benzamidine, 1-mM sodium
orthovanadate, and 2-µM cantharidin) and protease (1-µL to 20 mg of tissue as per
Roche Diagnostics) inhibitors. A targeted ﬁnal concentration of 0.2-g tissue per mL
PBS solution was applied in all samples. Blood samples were stored with the anticoagulant disodium (ethylenedinitrilo)tetraacetic acid (EDTA) to prevent coagulation of samples. Samples were then stored at −80 °C until analysis.
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ELISA analyses. A detailed protocol for ELISA Assays was provided by the
respective supplier of the kits: https://www.lsbio.com/elisakits/manualpdf/lsf24977.pdf, Acetylcholine: http://www.abcam.com/ps/products/65/ab65345/
documents/ab65345%20Choline%20Acetylcholine%20Assay%20Kit%20protocol%
20v11%20(website).pdf, PI3K Activation Proﬁle (Akt/GSK/p70S6K): https://www.
thermoﬁsher.com/order/catalog/product/85-86048-11, SRC: https://www.lsbio.
com/elisakits/manualpdf/ls-f11230.pdf, P38 (MAPK): https://www.thermoﬁsher.
com/order/catalog/product/85-86022-11.
HPLC analyses. Serum samples were injected directly into the machine with no
pre-treatment. Tissue homogenates were initially homogenized with 0.1-M perchloric acid and centrifuged for 15 min, after which the supernatant was separated,
and the sample injected into the HPLC. Catecholamines norepinephrine and
epinephrine were analyzed by HPLC with inline ultraviolet detector. The test
column used in this analysis was a Supelco Discovery C18 (15-cm × 4.6-mm inside
diameter, 5-µm particle size). A biphasic mobile phase comprised of [A] acetonitrile: [B] 50 = mM KH2PO4, set to pH 3 (with phosphoric acid). The solution was
then buffered with 100-mg/L EDTA and 200-mg/L 1-octane-sulfonic acid. Final
concentration of mobile phase mixture was set to 5:95, A:B. A ﬂow rate of 1 mL/
min was used to improve overall peak resolution while the column was held to a
consistent 20 °C to minimize pressure compaction of the column resulting from the
viscosity of the utilized mobile phase. The UV detector was maintained at a
254-nm wavelength, which is known to capture the absorption for catecholamines
including norepinephrine, epinephrine, and dopamine.
Immunohistochemistry and histology protocols. Tissue extraction and parafﬁn
block conversion performed as follows. Put tissue (rat brain) into ﬁxative immediately and ﬁx ~24 h in 10% formalin at 4 °C. Process tissue with the following
protocol (with vacuum and pressure during each incubation): 70% ethanol, 37 °C,
40 min, 80% ethanol, 37 °C, 40 min, 95% ethanol, 37 °C, 40 min, 95% ethanol,
37 °C, 40 min, 100% ethanol, 37 C, 40 min, 100% ethanol, 37 °C, 40 min, xylene,
37 °C, 40 min, xylene, 37 °C, 40 min, parafﬁn, 65 °C, 40 min, parafﬁn, 65 °C,
40 min, parafﬁn, 65 °C, 40 min. Sample is then left in this parafﬁn until ready for
embedding (not to exceed ~12–18 h).
Embed into Parafﬁn block for sectioning, allow block to cool/harden before
sectioning. Section 5-µm thick, ﬂoat on 50 °C water bath for collection. Use positively
charged slides and try to position the tissue in the same orientation for every slide. Air
dry slides. Overnight at room temperature seems to be the best for drying but the
slides can be placed on a 40 °C slide warmer to speed up the drying process, but do
not leave slides more than an hour on the warmer. Store slides at 4 °C.
Formalin-ﬁxed parafﬁn-embedded (FFPE) tissue samples (rat brains) were
baked at 65 °C for 1 h. Slides were deparafﬁnized with xylene, rehydrated by
decreasing ethanol concentration washes, and then processed for antigen retrieval. A
two-step antigen retrieval method was developed speciﬁcally for multiplexing with
FFPE tissues, which allowed for the use of antibodies with different antigen retrieval
conditions to be used together on the same samples. Samples were then incubated in
PBS with 0.3% Triton X-100 for 10 min at ambient temperature before blocking
against nonspeciﬁc binding with 10% (wt/vol) donkey serum and 3% (wt/vol)
bovine serum albumin (BSA) in 1× PBS for 45 min at room temperature. Primary
antibody c-Fos (Santa Cruz-SC52; sc-166940) was diluted to optimized
concentration (5 μg/mL) and applied for 1 h at room temperature in PBS/3% (vol/
vol) BSA. Samples were then washed sequentially in PBS, PBS-TritonX-100, and
then PBS again for 10 min, each with agitation. In the case of secondary antibody
detection, samples were incubated with primary antibody species-speciﬁc
secondary Donkey IgG conjugated to either Cy3 or Cy5. Slides were then washed as
above and stained in DAPI (10 μg/mL) for 5 min, rinsed again in PBS, and then
mounted with antifade media for image acquisition. Whole-tissue images were
acquired on ﬂuorescence microscope (Olympus IX81) at ×10 magniﬁcation.
Autoﬂuorescence, which is typical of FFPE tissues, needs to be properly
characterized and separated from target ﬂuorophore signals. We used
autoﬂuorescence removal processes, wherein an image of the unstained sample is
acquired in addition to the stained image. The unstained and stained images are
normalized with respect to their exposure times and the dark pixel value (pixel
intensity value at zero exposure time). Each normalized autoﬂuorescence image is
then subtracted from the corresponding normalized stained image. We ensured
that the same region in the stimulated and control samples were imaged.
Histological assessment of stimulated tissue. Spleen from stimulated rats and
control rats were processed into parafﬁn blocks as described above. Parafﬁnembedded sections were cleared and stained for H&E following standard protocol
reported in the literature and scanned on a bright ﬁeld scanner (Olympus). H&E
images were qualitatively assessed for morphological difference and no signiﬁcant
difference was noticed between stimulated and control samples (Supplementary
Figure 7).
Alternate pulse repetition periods and pulse amplitude. Data for blood glucose
and/or splenic NE, ACH, and TNF concentrations in ultrasound-stimulated animals (with (Supplementary Figures 8–10) or without (Supplementary Figure 7) LPS
injection) using alternative ultrasound-stimulation parameters were compared to
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those presented in the main text. We evaluated the effect of ultrasound neuromodulation in naive/non-LPS treated animals (Supplementary Figure 7) and animals treated with alternative pulse repetition periods and pulse lengths (summary
of results in Supplementary Figures 8–10).
Electrode-based vagal nerve stimulation (VNS) protocol. Male
Sprague–Dawley rats were anesthetized with 2–4% isoﬂurane. A single incision was
made along the neck exposing the cervical portion of the trapezius, sternocleidomastoid and masseter muscles for blunt dissection exposing the left cervical vagus
nerve. The microelectrode was placed along the main trunk of the exposed cervical
vagus nerve. Electrical stimulation using three settings (5 V, 30 Hz, 2 ms; 5 V, 5 Hz,
2 ms; and 1 V, 5 Hz, 2 ms) was generated using a BIOPAC MP150 module under
the control of the AcqKnowledge software (Biopac Systems). Rats underwent 3 min
of VNS before and after IP injection of 10-mg/kg LPS. Following injection of
10 mg/kg LPS, a saline-soaked pad was used to hydrate the area and the cervical
region was sutured closed to maintain integrity of the physiologic site. Rats were
euthanized 60 min after LPS injection as described above, and spleen and blood
samples were obtained for TNF determination as described above. In rats subjected
to sham surgery, the vagus nerve was exposed, but not touched or manipulated.
Heart rate monitoring and analysis. Heart rate (during either ultrasound or
electrode stimulation experiments) was monitored using a commercial infrared
oximeter and physiological monitoring system (Starr Lifesciences) using the
manufacturer’s instructions. During the stimulation protocols, the foot clip sensor
(provided by the manufacturer) was placed on the footpad of the animal. The
animal was allowed to acclimate for at least 5 min prior to measurement, a time
point found sufﬁcient for animals to recover to normal heart rate activities and
physiological reading in controls. Measurement was recorded before (2-min
recording periods), during, and after (2-min recording periods) the stimulation
with either the electrical microelectrode or ultrasound probe.
cFos analysis and other measures of US-induced activation. LPS-U/S stimulated and sham animals were rapidly euthanized, and brains removed and transferred to 10% paraformaldehyde for 24 h, after which they were transferred to a
30% sucrose solution and stored for 4 °C prior to parafﬁn embedding (detailed in
the IHC section above). Coronal section (5–10 µm) were cut by cryostat. Structures
were anatomically deﬁned according to an anatomical atlas. Quantiﬁcation of c-Fos
positive cells was counted with a ﬁxed sample window across at least four sections
by an experimenter blinded to the treatment conditions associated with each distinct coronal section. Regions of interest were as follows: paraventricular hypothalamic nucleus, ARC, VMN, DMN, LH, and mammillothalamic tract (all
structures visible in coronal slices taken between Bregma −2.56 to −3.60 mm). The
number of c-Fos positive cells in each group were expressed as a % of cFos+ cells
as compared to Sham-stimulated control littermates.
In addition to the hypothalamic speciﬁc cFos-staining analysis performed in the
main Bregma −11.3 to −14.08 mm, text/ﬁgures, the team sectioned and analyzed
ultrasound induced activation within the NTS. The NTS is a brainstem nucleus
known to harbor purely sensory nuclei (including ﬁbers from the vagus nerve), and
project to areas of the brain involved with autonomic regulation (including the
hypothalamus; see Supplementary Figure 11 for a description of these neural
pathways). The increased staining of the activation speciﬁc marker in the
ultrasound stimulated animals (Fig. 7) agrees with the other ﬁndings (i.e.,
hypothalamic neurotransmitter and protein data, and MRI data) and suggests
ultrasound induction of a nerve-mediated modulation of hypothalamic metabolic
control centers. This additional supplemental data (Supplementary Figure 12)
suggests that this ultrasound effect is at least in part mediated through direct
sensory pathways.
Diffusion functional MRI. Neuronal activation is typically detected using bloodoxygenation-level-dependent (BOLD) fMRI54; brain regions with increased metabolic demand lead to higher cerebral blood ﬂow, an increased supply of oxygenated
blood, and decreased gradient echo signal. Sensitivity to the BOLD effect requires
the use of fast gradient echo acquisitions; this causes undesired signal loss in brain
areas next to air pockets, such as sinuses and ear canals, and hinders detection of
neuronal activation near those speciﬁc brain areas. Alternatively, to minimize
signal loss in areas characterized by large ﬁeld inhomogeneities, spin echo (or
double spin echo) diffusion-weighted imaging (DWI) can be used for detecting
neuronal activation44–46 or nerve activation driven by external neuromodulators47.
In DWI-fMRI, a volume increase in the slow-diffusing, presumably intracellular,
water pool or an increase in water diffusion (or ADC) are assigned physical
changes caused by neuronal activation.
Ten Sprague–Dawley rats were anesthetized using 3% Isoﬂurane and placed
supine, with their heads inserted in a birdcage coil. The abdomen region was
coupled through a gel/water ﬁlled cone to an MR-compatible U/S probe (f =
1.47 MHz), focusing on the porta hepatis, a liver region known to contain glucose
sensitive neurons. Supplementary Figure 13a depicts a schematic of the
experimental setup, including the US probe connected to RF ampliﬁer/signal
generator.
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Data were acquired on a 3T scanner (MR750, GE Healthcare). An SPGR T1
acquisition was followed by six blocks of DWI images, with a TE/TR of 82/3400
ms, using 3/4 averages for the b = 0/b = 1000 s/mm2 and 0.6/1-mm in-plane/outof-plane spatial resolution. An additional reverse polarity DWI acquisition was
acquired for distortion correction purposes55. Following the LPS injection, the ﬁrst
US treatment, a wait time and the second US treatment, another 6 blocks of DWI
images were acquired. Each ultrasound treatment lasted 60 s, during which square
wave pulses were applied at 150/350-μs on/off periods. The sound pressure at the
focal point was approximately 3.2 MPa. Supplementary Figure 13b depicts a
summary of the experimental timing. This protocol was applied to 6 rats; for the
remaining 4, the last DWI blocks immediately followed the LPS injection, with no
US treatment.
A cross-correlation coefﬁcient (ccc) between the T1 images and the (distortioncorrected) b = 0 DWI images of at least 0.5 was used to identify slices to be used for
further analysis. ADCs were calculated for the pre- and post-treatment images; preand post-treatment image data were pooled together for statistical analysis. A rigid
registration between the T1 images and a rat atlas was used to determine regions in
which pixel-by-pixel t-tests indicated signiﬁcant changes. The registration
transformation from the T1 and atlas images was applied to the distortioncorrected DWI and ADC images.
Supplementary Figure 14 shows an example of the T1/b = 0 DWI acquisition in
one rat after distortion correction; only red-highlighted slices met ccc > 0.5 and
were kept for statistical analysis. To follow the effects of LPS and US treatment on
blood glucose level, blood samples were obtained from the tail vein immediately
before the ﬁrst MRI scan and at 30 min after LPS injection; blood glucose
concentration was measured by a OneTouch Elite glucometer (LifeScan; Johnson &
Johnson).
Figure 7b shows an example overlay between the activation maps/SPGR volume
(left) and the atlas/SPGR volume (right). Note the ADC change in both PVNs of
the hypothalamus (red arrows, left image), consistent with ultrasound-induced
neuromodulation. Figure 7d summarizes the results in a bar graph and
Supplementary Table 2 details the explicit results in all 10 animals. Three of six rats
showed signiﬁcant neuromodulation in the PVNs; none of the control animals
showed such change in neural activity. Furthermore, the hyperglycemia observed in
the non-US-treated animals was not observed in the US-treated animals.

Data availability
Data generated or analyzed during this study were made available within the published
article where possible (and its Supplementary Information ﬁles); any dataset generated
during and/or analyzed during the current study may also be made available from the
corresponding author on reasonable request. Microscopy images utilized in the manuscript have been made available at https://datadryad.org. (https://doi.org/10.5061/dryad.
md888qr).
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